CN1838964A - 肺病的治疗与预防 - Google Patents

肺病的治疗与预防 Download PDF

Info

Publication number
CN1838964A
CN1838964A CNA038145170A CN03814517A CN1838964A CN 1838964 A CN1838964 A CN 1838964A CN A038145170 A CNA038145170 A CN A038145170A CN 03814517 A CN03814517 A CN 03814517A CN 1838964 A CN1838964 A CN 1838964A
Authority
CN
China
Prior art keywords
seq
inhibitor
composition
leu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038145170A
Other languages
English (en)
Chinese (zh)
Inventor
C·G·科克拉内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of CN1838964A publication Critical patent/CN1838964A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNA038145170A 2002-04-25 2003-04-25 肺病的治疗与预防 Pending CN1838964A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37596802P 2002-04-25 2002-04-25
US60/375,968 2002-04-25

Publications (1)

Publication Number Publication Date
CN1838964A true CN1838964A (zh) 2006-09-27

Family

ID=29270737

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038145170A Pending CN1838964A (zh) 2002-04-25 2003-04-25 肺病的治疗与预防

Country Status (13)

Country Link
US (2) US7863241B2 (https=)
EP (1) EP1558273B1 (https=)
JP (2) JP4651946B2 (https=)
KR (2) KR101036058B1 (https=)
CN (1) CN1838964A (https=)
AT (1) ATE520411T1 (https=)
AU (1) AU2003223718B2 (https=)
CA (1) CA2483102C (https=)
IL (2) IL164795A0 (https=)
MX (1) MXPA04010560A (https=)
NZ (1) NZ536796A (https=)
WO (1) WO2003090682A2 (https=)
ZA (1) ZA200408573B (https=)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101897720A (zh) * 2010-07-27 2010-12-01 北京华禧联合科技发展有限公司 一种治疗呼吸道疾病的药物组合物
CN101687006B (zh) * 2007-06-01 2013-10-16 奇斯药制品公司 具有改善特性的重建表面活性剂
CN102083411B (zh) * 2007-12-19 2014-12-03 Ucl商业股份有限公司 载体
CN109789193A (zh) * 2016-09-13 2019-05-21 普罗瑟拉生物公司 使用间α抑制蛋白治疗肺病的方法
CN112703009A (zh) * 2018-08-17 2021-04-23 宾夕法尼亚大学董事会 治疗急性肺损伤的组合物和方法
CN113164425A (zh) * 2018-10-30 2021-07-23 佛罗里达大学研究基金会公司 用于治疗囊性纤维化的氨基酸组合物和方法
CN113271928A (zh) * 2018-10-19 2021-08-17 俄亥俄州国家创新基金会 用于肺部炎症治疗的纳米载体
CN115245559A (zh) * 2021-04-25 2022-10-28 上海萨美细胞技术有限公司 一种用于治疗肺损伤的药物
CN115379828A (zh) * 2020-04-08 2022-11-22 代表亚利桑那大学的亚利桑那校董会 用于治疗和预防肺病的组合物和方法
WO2024174948A1 (zh) * 2023-02-20 2024-08-29 成都佩德生物医药有限公司 多肽pd-dp-005在制备治疗肺部疾病药物中的应用及其药物
CN120000688A (zh) * 2025-04-16 2025-05-16 山东杰凯生物科技有限公司 基于干细胞外囊泡的雾化吸入组合物及其制备方法、应用

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223718B2 (en) 2002-04-25 2007-08-16 The Scripps Research Institute Treatment and prevention of pulmonary conditions
EP1694314A4 (en) * 2003-12-04 2009-07-01 Scripps Research Inst TREATMENT AND PREVENTION OF ASTHMA
WO2005073246A2 (en) * 2004-01-20 2005-08-11 Discovery Laboratories, Inc. Method for preparing kl4 lung surfactant
WO2005087249A1 (ja) * 2004-03-11 2005-09-22 Kurume University プロテアーゼ阻害剤及び疾患の予防又は治療剤
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US7553810B2 (en) 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US7608579B2 (en) 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US7468350B2 (en) 2004-06-16 2008-12-23 Pneumrx, Inc. Glue composition for lung volume reduction
CA2570261C (en) 2004-07-08 2014-06-10 Pneumrx, Inc. Pleural effusion treatment device, method and material
EP1791555B1 (en) * 2004-09-10 2013-03-13 Pharmaorigin ApS Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
WO2006071102A1 (en) * 2004-12-30 2006-07-06 Dobeel Co., Ltd. Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same
GB0510463D0 (en) * 2005-05-23 2005-06-29 Britania Pharmaceuticals Ltd Improvements in or relating to organic materials
WO2006136962A2 (en) * 2005-06-24 2006-12-28 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract
WO2007005672A2 (en) * 2005-06-30 2007-01-11 The Scripps Research Institute Treatment and prevention of respiratory diseases and conditions
WO2008121811A2 (en) * 2007-03-29 2008-10-09 National Jewish Medical And Research Center Surfactant lipids, compositions thereof, and uses thereof
AU2008259768B2 (en) * 2007-06-05 2013-08-29 Paka Pulmonary Pharmaceuticals, Inc. Compositions for delivering medicaments into the lungs, uses thereof
US20110142914A1 (en) * 2007-12-06 2011-06-16 Cytotech Labs, Llc Inhalable compositions having enhanced bioavailability
WO2010068754A2 (en) * 2008-12-10 2010-06-17 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
EP2391379B1 (en) 2009-01-30 2017-08-02 Alphabeta AB Compound and method for treatment of alzheimer's disease
US8434479B2 (en) * 2009-02-27 2013-05-07 Covidien Lp Flow rate compensation for transient thermal response of hot-wire anemometers
JP5622728B2 (ja) * 2009-08-06 2014-11-12 一般財団法人化学及血清療法研究所 咳嗽抑制効果を持つ血漿タンパク質
DK2308489T3 (da) * 2009-10-05 2014-03-24 Nutri Fit Gmbh & Co Kg Sammensætninger til anvendelse ved behandling eller forebyggelse af lungeskade, der fremkaldes af en stofskiftebelastning samt fremgangsmåder til forøgelse af pattedyrs fysiske kapacitet
AU2010315325B2 (en) 2009-11-03 2014-11-27 Grifols Therapeutics Inc. Composition, method, and kit for alpha-1 proteinase inhibitor
PT2503995T (pt) 2009-11-24 2017-11-23 Grifols Therapeutics Inc Métodos de liofilização, composições e kits
GB201003559D0 (en) * 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
SG10202010355PA (en) 2010-03-12 2020-11-27 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
AU2010356144B2 (en) 2010-06-24 2015-06-04 Alphabeta Ab Compound and method for treatment of Alzheimer's disease and familial dementia
EP2637681A4 (en) * 2010-11-04 2015-09-23 Univ Oklahoma PEPTIDE COMPOSITIONS FOR DOWN-REGULATING THE TLR-4 SIGNAL PATH AND METHOD FOR THE PRODUCTION AND USE THEREOF
US20130184202A1 (en) * 2011-02-08 2013-07-18 Changjiang Guo Peptide Inhibitors and Methods of Use Thereof
WO2012138284A1 (en) 2011-04-05 2012-10-11 Alphabeta Ab Amyloidosis target useful in methods of treatment and for screening of compounds
BR112013026313A8 (pt) * 2011-04-12 2018-01-30 Moerae Matrix Inc composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação anormal de fibroblastos e depósito de matriz extracelular
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
EP2720680B1 (en) 2011-06-17 2020-02-12 Berg LLC Inhalable pharmaceutical compositions
US9089657B2 (en) 2011-10-31 2015-07-28 Covidien Lp Methods and systems for gating user initiated increases in oxygen concentration during ventilation
WO2013188016A2 (en) * 2012-05-04 2013-12-19 Discovery Laboratories, Inc. Surfactant therapy for exposure to ionizing radiation
JP2016532456A (ja) 2013-09-18 2016-10-20 ジェームス・クック・ユニバーシティー 改変型抗炎症性タンパク質及び使用方法
CN105764523A (zh) * 2013-09-18 2016-07-13 詹姆斯库克大学 抗炎蛋白及使用方法
WO2015061412A1 (en) * 2013-10-22 2015-04-30 The Scripps Research Institute Methods and compositions for promoting bronchioli dilatation
US20180221462A1 (en) * 2014-08-26 2018-08-09 Proteo Biotech Ag Use of elafin for disorders associated with elastase independent increase in troponin
EP3300474A4 (en) 2015-04-27 2019-01-30 OmniActive Health Technologies Limited BETTUBO TOXIN COMPOSITIONS, METHOD FOR THE PRODUCTION THEREOF AND USES THEREOF
US10239847B1 (en) 2016-03-03 2019-03-26 Cellactin Method for 2-oxothiazolidine-4-carboxylic acid for cellular glutathione
CN110461351B (zh) * 2017-03-31 2024-03-26 艾娜呼吸私人有限公司 用tlr2激动剂治疗呼吸道感染
CA3085944A1 (en) * 2017-12-21 2019-06-27 Civitas Therapeutics, Inc. Surfactant formulations for inhalation
CN112654344A (zh) * 2018-04-17 2021-04-13 板层小体生物医学有限公司 抗纤维化组合物
CA3117213A1 (en) * 2018-10-23 2020-04-30 George Edward Hoag Composition and method for treating the lungs
CA3145702A1 (en) * 2019-08-01 2021-02-04 Philip A. Pemberton Oxidation-resistant serpins
KR102276935B1 (ko) * 2020-02-06 2021-07-12 한양대학교 산학협력단 신규한 비올라크산틴 고생산 클로렐라 불가리스 균주 및 이로부터 비올라크산틴을 생산하는 방법
WO2024097169A1 (en) * 2022-11-01 2024-05-10 National Jewish Health Treatment of coronavirus infections with antimicrobial phospholipid compositions

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57144224A (en) * 1981-03-02 1982-09-06 Mochida Pharmaceut Co Ltd Remedy for respiratory dieseases
US4916117A (en) * 1986-12-24 1990-04-10 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US5260273A (en) * 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US5164369A (en) * 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5707634A (en) * 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
NO177716C (no) * 1989-06-09 1995-11-08 Zeneca Ltd Fremgangsmåte for fremstilling av terapeutisk aktive polypeptider, DNA-sekvens, ekspresjonsvektor og antistoff
AU638474B2 (en) * 1989-07-11 1993-07-01 Genentech Inc. Surfactant compositions and methods
US5993805A (en) * 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5272252A (en) * 1991-11-04 1993-12-21 Merrell Dow Pharmaceuticals Inc. Synthetic lung surfactant having antioxidant properties
AU664112B2 (en) * 1992-07-31 1995-11-02 Merrell Dow Pharmaceuticals Inc. Synthetic peptide lung surfactants having covalently bonded antioxidants
US5734014A (en) * 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5301644A (en) * 1993-06-16 1994-04-12 Kohler Co. Fuel shut-off mechanism for internal combustion engines
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
NZ284766A (en) * 1994-06-02 1998-06-26 Merrell Pharma Inc Perfluoro amino ketones; medicaments as elastase inhibitors
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5878912A (en) * 1995-12-26 1999-03-09 Stein; Myron Duct disinfecting method and apparatus
US5874029A (en) * 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US5833891A (en) * 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5780440A (en) * 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
AU5719798A (en) * 1996-12-31 1998-07-31 Inhale Therapeutic Systems, Inc. Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
US6051257A (en) * 1997-02-24 2000-04-18 Superior Micropowders, Llc Powder batch of pharmaceutically-active particles and methods for making same
JPH11147832A (ja) * 1997-11-18 1999-06-02 Noevir Co Ltd 好中球エラスターゼ阻害剤
JP3796340B2 (ja) * 1997-11-18 2006-07-12 株式会社ノエビア セリンプロテアーゼ阻害剤
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US5883084A (en) * 1998-06-08 1999-03-16 Clarion Pharmaceuticals Inc. Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine
US6223455B1 (en) * 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
US7053176B1 (en) * 1999-09-16 2006-05-30 Altana Pharma Ag Combination of C1-INH and lung surfactant for the treatment of respiratory disorders
IL150485A0 (en) * 1999-12-28 2002-12-01 Novartis Ag Method of achieving persistent transgene expression
EP1251868A1 (en) * 2000-01-06 2002-10-30 Eli Lilly & Company Combination therapy for the treatment of inflammatory and respiratory diseases
AU2003223718B2 (en) 2002-04-25 2007-08-16 The Scripps Research Institute Treatment and prevention of pulmonary conditions
US6819898B2 (en) * 2002-11-22 2004-11-16 Kabushiki Kaisha Toshiba Image forming apparatus including stopping member and backstop member to stop rotation of revolver type developing unit

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101687006B (zh) * 2007-06-01 2013-10-16 奇斯药制品公司 具有改善特性的重建表面活性剂
CN102083411B (zh) * 2007-12-19 2014-12-03 Ucl商业股份有限公司 载体
CN101897720A (zh) * 2010-07-27 2010-12-01 北京华禧联合科技发展有限公司 一种治疗呼吸道疾病的药物组合物
CN109789193A (zh) * 2016-09-13 2019-05-21 普罗瑟拉生物公司 使用间α抑制蛋白治疗肺病的方法
CN112703009B (zh) * 2018-08-17 2024-06-11 宾夕法尼亚大学董事会 治疗急性肺损伤的组合物和方法
CN112703009A (zh) * 2018-08-17 2021-04-23 宾夕法尼亚大学董事会 治疗急性肺损伤的组合物和方法
CN113271928A (zh) * 2018-10-19 2021-08-17 俄亥俄州国家创新基金会 用于肺部炎症治疗的纳米载体
US12221471B2 (en) 2018-10-19 2025-02-11 Ohio State Innovation Foundation Nanocarriers for lung inflammation therapy
CN113164425A (zh) * 2018-10-30 2021-07-23 佛罗里达大学研究基金会公司 用于治疗囊性纤维化的氨基酸组合物和方法
CN115379828A (zh) * 2020-04-08 2022-11-22 代表亚利桑那大学的亚利桑那校董会 用于治疗和预防肺病的组合物和方法
CN115245559A (zh) * 2021-04-25 2022-10-28 上海萨美细胞技术有限公司 一种用于治疗肺损伤的药物
WO2024174948A1 (zh) * 2023-02-20 2024-08-29 成都佩德生物医药有限公司 多肽pd-dp-005在制备治疗肺部疾病药物中的应用及其药物
CN120000688A (zh) * 2025-04-16 2025-05-16 山东杰凯生物科技有限公司 基于干细胞外囊泡的雾化吸入组合物及其制备方法、应用
CN120000688B (zh) * 2025-04-16 2025-08-05 山东杰凯生物科技有限公司 基于干细胞外囊泡的雾化吸入组合物及其制备方法、应用

Also Published As

Publication number Publication date
US20050070477A1 (en) 2005-03-31
ATE520411T1 (de) 2011-09-15
KR20110017465A (ko) 2011-02-21
IL164795A (en) 2011-02-28
US20120189602A1 (en) 2012-07-26
EP1558273B1 (en) 2011-08-17
AU2003223718B2 (en) 2007-08-16
US7863241B2 (en) 2011-01-04
AU2003223718A1 (en) 2003-11-10
EP1558273A2 (en) 2005-08-03
EP1558273A4 (en) 2008-07-16
NZ536796A (en) 2007-03-30
WO2003090682A2 (en) 2003-11-06
JP2005529885A (ja) 2005-10-06
WO2003090682A3 (en) 2004-09-16
IL164795A0 (en) 2005-12-18
AU2003223718C1 (en) 2003-11-10
CA2483102A1 (en) 2003-11-06
ZA200408573B (en) 2006-03-29
CA2483102C (en) 2013-06-18
JP2011001383A (ja) 2011-01-06
KR20050019073A (ko) 2005-02-28
JP4651946B2 (ja) 2011-03-16
KR101036058B1 (ko) 2011-05-19
MXPA04010560A (es) 2005-08-15

Similar Documents

Publication Publication Date Title
CN1838964A (zh) 肺病的治疗与预防
CN112996530B (zh) 小窝蛋白-1肽的干粉制剂及其使用方法
CN1224419C (zh) 用于改善动脉粥样硬化的口服给药的肽
JP6038452B2 (ja) 生物学的に活性なペプチド
JP2005529885A5 (https=)
HK1044898A1 (zh) 載脂蛋白a-i激動劑及其治療脂血異常症的用途
CN1280501A (zh) 载脂蛋白a－i激动剂及其在异常脂血相关病症的治疗中的应用
CN1280500A (zh) 载脂蛋白a－i激动剂及其在异常脂血相关病症的治疗中的应用
CN103990111B (zh) 减少炎症介质释放的方法和可用于该方法的肽
CN1057099C (zh) 新的合成肽，其中间体及其生产方法
CN1229138C (zh) 加速粘液纤毛的清除速率的方法
CN1310679C (zh) 获得持续的转基因表达的方法
CN1642568A (zh) 治疗细胞消融治疗引起的胃肠毒性的方法和组合物
WO2015061412A1 (en) Methods and compositions for promoting bronchioli dilatation
HK1090934A (en) Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20060927